loading
Precedente Chiudi:
$21.36
Aprire:
$21.34
Volume 24 ore:
2.06M
Relative Volume:
1.03
Capitalizzazione di mercato:
$3.73B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
118.00
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-5.60%
1M Prestazione:
-1.05%
6M Prestazione:
+13.83%
1 anno Prestazione:
+34.09%
Intervallo 1D:
Value
$21.18
$21.69
Intervallo di 1 settimana:
Value
$21.16
$23.09
Portata 52W:
Value
$13.40
$25.23

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Nome
Acadia Pharmaceuticals Inc
Name
Telefono
858-558-2871
Name
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Name
Dipendente
654
Name
Cinguettio
@acadiapharma
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
ACAD's Discussions on Twitter

Confronta ACAD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
21.24 3.73B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-21 Aggiornamento Deutsche Bank Hold → Buy
2025-02-11 Iniziato Deutsche Bank Hold
2025-01-03 Downgrade Guggenheim Buy → Neutral
2024-10-10 Ripresa Raymond James Mkt Perform
2024-08-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-06-27 Iniziato BMO Capital Markets Outperform
2024-03-12 Downgrade Mizuho Buy → Neutral
2024-03-12 Reiterato Needham Buy
2024-01-30 Iniziato Robert W. Baird Outperform
2024-01-24 Aggiornamento Needham Hold → Buy
2023-12-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2023-12-14 Downgrade Deutsche Bank Buy → Hold
2023-12-13 Iniziato Citigroup Buy
2023-12-12 Iniziato Deutsche Bank Buy
2023-11-06 Aggiornamento Mizuho Neutral → Buy
2023-10-17 Iniziato UBS Buy
2023-10-10 Aggiornamento JP Morgan Neutral → Overweight
2023-01-03 Aggiornamento Guggenheim Neutral → Buy
2022-11-04 Downgrade Goldman Neutral → Sell
2022-11-01 Iniziato Loop Capital Hold
2022-08-08 Downgrade Citigroup Buy → Neutral
2022-08-05 Downgrade Citigroup Buy → Neutral
2022-06-21 Downgrade Jefferies Buy → Underperform
2022-06-16 Aggiornamento Jefferies Hold → Buy
2022-03-16 Aggiornamento Canaccord Genuity Hold → Buy
2022-02-09 Aggiornamento H.C. Wainwright Neutral → Buy
2022-01-05 Aggiornamento Citigroup Neutral → Buy
2021-12-21 Downgrade Guggenheim Buy → Neutral
2021-11-01 Aggiornamento Guggenheim Neutral → Buy
2021-10-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-23 Ripresa Needham Hold
2021-06-10 Iniziato Berenberg Hold
2021-04-07 Downgrade H.C. Wainwright Buy → Neutral
2021-04-06 Downgrade Canaccord Genuity Buy → Hold
2021-04-06 Downgrade Goldman Buy → Neutral
2021-04-06 Downgrade Jefferies Buy → Hold
2021-04-06 Downgrade Mizuho Buy → Neutral
2021-04-05 Downgrade Raymond James Outperform → Mkt Perform
2021-03-10 Downgrade BofA Securities Buy → Neutral
2021-03-09 Downgrade Citigroup Buy → Neutral
2021-03-09 Downgrade Guggenheim Buy → Neutral
2021-03-09 Reiterato H.C. Wainwright Buy
2021-03-09 Downgrade Raymond James Strong Buy → Outperform
2021-03-09 Downgrade Stifel Buy → Hold
2020-12-16 Iniziato Mizuho Buy
2020-11-16 Aggiornamento Raymond James Outperform → Strong Buy
2020-08-25 Iniziato Raymond James Outperform
2020-08-20 Iniziato Morgan Stanley Overweight
2020-07-07 Aggiornamento Stifel Hold → Buy
2020-04-16 Iniziato Jefferies Buy
2020-03-31 Aggiornamento Goldman Neutral → Buy
2020-03-06 Iniziato Citigroup Buy
2019-12-16 Iniziato Guggenheim Buy
2019-10-24 Iniziato Oppenheimer Perform
2019-10-01 Iniziato RBC Capital Mkts Outperform
2019-09-13 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-09-10 Aggiornamento Canaccord Genuity Hold → Buy
2019-07-23 Reiterato Needham Buy
2018-12-10 Iniziato Canaccord Genuity Hold
2018-09-21 Aggiornamento Piper Jaffray Neutral → Overweight
2018-08-09 Reiterato Stifel Hold
2018-08-07 Iniziato Stifel Hold
2018-08-06 Downgrade Piper Jaffray Overweight → Neutral
2017-10-06 Ripresa Goldman Neutral
Mostra tutto

Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie

pulisher
Jun 18, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com

Jun 18, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 17, 2025
pulisher
Jun 14, 2025

Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 12, 2025

US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey

Jun 11, 2025
pulisher
Jun 10, 2025

Acadia wins patent appeal for key drug composition - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Acadia gets court approval related to Nuplazid patent - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies - Life Sciences Intellectual Property Review

Jun 10, 2025
pulisher
Jun 10, 2025

ACAD Patent Victory Secures Nuplazid Exclusivity Till 2030 | ACA - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

US appeals court upholds Acadia’s patent for Parkinson’s drug in MSN Labs case - BusinessLine

Jun 10, 2025
pulisher
Jun 09, 2025

Acadia secures NUPLAZID patent protection through 2030 By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ. - Law360

Jun 09, 2025
pulisher
Jun 09, 2025

Federal Court Upholds Acadia Pharmaceuticals (ACAD) Patent Victo - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Victory - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals Again Prevails in Appeal Upholding Patent for Parkinson's Drug - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : ACADIA Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Drug - U.S. News & World Report

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia gets court approval related to Nuplazid patent (ACAD) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals says Appeals Court confirms validity of NUPLAZID patent - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia secures NUPLAZID patent protection through 2030 - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharma (ACAD) announces affirmation from U.S. Court of Appeals in favor of Acadia in NUPLAZID patent - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent - Yahoo

Jun 09, 2025
pulisher
Jun 06, 2025

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $3 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan raises Acadia Pharmaceuticals stock price target to $30 - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from J - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from JP Morgan | ACAD Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan raises Acadia Pharmaceuticals stock price target to $30 By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Acadia Pharmaceuticals price target raised to $30 from $26 at JPMorgan - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $30 Following Patent Win | ACAD Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Insider Sell: Laura Brege Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Secu - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Securities | ACAD Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 | ACAD Stock News - GuruFocus

Jun 05, 2025

Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):